Trovagene's Q4 Revenues, Loss Rise | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Monday that its fourth-quarter revenues increased sharply as its net loss climbed on a change in fair value of derivative instruments related to warrants.

The San Diego-based molecular diagnostics developer brought in total revenues of $163,000 for the three months ended Dec. 31, compared to $34,000 for the fourth quarter of 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.